Dihexa

I’m going to be straight with you — Dihexa is one of the most fascinating and most problematic compounds I’ve come across in years of researching nootropics. On paper, the mechanism is unlike anything else out there. A peptide that doesn’t just tweak your neurotransmitters but actually helps your brain grow new synaptic connections? That sounds like the holy grail of cognitive enhancement.

Then you dig into the research. And the story gets complicated fast.

The scientist behind the key mechanistic study was found to have fabricated data. The CEO of the company commercializing it resigned over the scandal. The pharmaceutical derivative failed its big clinical trial. And yet — some independent animal research does show real promise.

So what do you do with all of that? That’s exactly what this guide is for.

The Short Version: Dihexa is a synthetic peptide analog of angiotensin IV that reportedly promotes new synaptic connections through the HGF/c-Met growth factor pathway. The mechanism is genuinely novel, but the foundational research has serious integrity issues (retracted papers, data fabrication), there are zero human studies on Dihexa itself, and the related pharma compound failed its Phase 2/3 trial. This is a high-risk compound that demands honest assessment, not hype.

What Is Dihexa?

Dihexa (also called PNB-0408) is a synthetic oligopeptide developed in the late 2000s by researchers Joseph Harding and John Wright at Washington State University. They’d been studying angiotensin IV — a naturally occurring brain peptide involved in memory and cognition — and wanted to create a version that was stable enough to survive digestion and cross the blood-brain barrier when taken orally. Most peptides can’t do that. Dihexa was designed to.

The basic idea is elegant. Your brain has a growth factor system called HGF/c-Met that promotes the physical growth of new synaptic connections — the wiring between neurons. Dihexa was engineered to activate this system, theoretically giving your brain the raw signal to build new infrastructure rather than just turning up the volume on existing pathways.

The researchers spun off a company called M3 Biotechnology (later renamed Athira Pharma) to develop Dihexa into a pharmaceutical drug. The pharma version, called fosgonimeton (ATH-1017), made it all the way to Phase 2/3 clinical trials for Alzheimer’s disease.

But here’s where the foundations-first philosophy really matters. Before you get excited about a cutting-edge peptide that might rewire your brain, you need to know that the ground this compound stands on has some serious cracks. And I don’t mean theoretical concerns — I mean documented research fraud.

The Research Integrity Problem You Need to Know About

Important: The key mechanistic paper for Dihexa — Benoist et al. (2014) in the Journal of Pharmacology and Experimental Therapeutics — has been retracted after Washington State University’s investigation found the figures contained falsified and/or fabricated data. Co-authors Leen Kawas and Joseph Harding were found solely responsible.

I’m putting this near the top because most Dihexa articles either bury it or skip it entirely. That’s not how I operate.

Leen Kawas, who co-authored the foundational papers and went on to become CEO of Athira Pharma, resigned in October 2021 after an investigation confirmed she altered images in her doctoral dissertation and at least four published papers. In January 2025, Athira Pharma paid approximately $4 million to settle False Claims Act allegations for failing to report the misconduct to federal agencies.

Does this mean Dihexa definitely doesn’t work? No. But it means the specific claim that Dihexa is “10 million times more potent than BDNF” — a number you’ll see repeated across the internet — comes directly from the compromised research. Treat that claim with extreme skepticism.

Some independent research does exist, and I’ll cover that honestly below. But you deserve to know the full picture before you spend your money.

How Does Dihexa Work?

Here’s the concept in plain English: most nootropics work by adjusting your brain’s chemical messengers — more dopamine here, less glutamate there. Dihexa supposedly works on a completely different level. Instead of tweaking the signals, it promotes the growth of new physical connections between neurons.

Think of it like the difference between turning up the speakers on a sound system versus actually running new speaker wire to rooms that didn’t have any. One changes the volume. The other changes the architecture.

The proposed mechanism works through the HGF/c-Met pathway. Hepatocyte growth factor (HGF) is a protein that, among many roles in the body, promotes dendritic spinogenesis — the growth of tiny protrusions on neurons where synapses form. Dihexa reportedly binds to HGF and amplifies its activity at the c-Met receptor, essentially telling your hippocampus to build more connection points.

An independent Chinese research group (Sun et al., 2021, Brain Sciences) found a second pathway: Dihexa activated PI3K/AKT signaling in Alzheimer’s model mice, reducing neuroinflammation by calming overactive astrocytes and microglia while shifting the balance from pro-inflammatory cytokines toward anti-inflammatory ones.

There’s also a credible piece of indirect evidence that Dihexa genuinely interacts with HGF. Multiple stem cell research groups — completely unrelated to the original WSU team — have independently validated that Dihexa functions as an HGF agonist. They use it as a cheap substitute for recombinant HGF protein when differentiating stem cells into liver cells. That’s not proof it does what the nootropics community claims in the brain, but it does confirm the compound has real biological activity at the HGF receptor.

The practical translation? If the mechanism holds up — and that’s a significant “if” given the retraction issues — Dihexa would represent a genuinely different category of cognitive support: structural rather than chemical. But the honest answer is we don’t fully know yet.

Benefits of Dihexa

Let me be direct about the evidence quality here. There are zero published human clinical trials on Dihexa itself. Everything below comes from animal studies or reports from the related pharmaceutical compound.

Reality Check: Most of what you’ll read online about Dihexa’s benefits comes from the original WSU research group — the same group implicated in data fabrication. I’m going to focus on what independent researchers have found, and I’ll flag when a study involves the original team.

What independent research actually shows:

A Chinese research team (Sun et al., 2021) tested Dihexa in APP/PS1 Alzheimer’s model mice and found it restored spatial learning, increased neuronal cell density, boosted synaptophysin expression (a marker of synaptic health), and reduced neuroinflammation. This is the strongest independent validation of Dihexa’s cognitive effects, though it’s still a single mouse study.

A systematic review by Ho & Nation (2018, Neuroscience & Biobehavioral Reviews) examined 32 studies on angiotensin IV and its analogs — including Dihexa — and found generally beneficial effects on memory tasks in cognitively impaired animals.

What didn’t work:

Wells et al. (2024, Journal of Huntington’s Disease) tested Dihexa in a Huntington’s disease rat model and found it did not protect against cognitive or motor deficits. Negative results matter. They tell you the compound isn’t a universal brain fix.

The fosgonimeton story:

The pharmaceutical derivative of Dihexa, fosgonimeton, showed some encouraging Phase 1 signals — including improved brain electrical activity in Alzheimer’s patients. But the Phase 2/3 LIFT-AD trial in 312 patients with mild-to-moderate Alzheimer’s failed its primary endpoint. Fosgonimeton did not significantly improve cognition versus placebo over 26 weeks (p = 0.70). That’s not even close to significance.

This doesn’t definitively rule out Dihexa for other uses or populations. But it should temper expectations considerably.

How to Take Dihexa

I want to be crystal clear: no human dosage has been established through clinical research. Everything in this section comes from anecdotal community reports and practitioner protocols.

Dosage ranges reported:

• Starting dose: 5–10 mg/day (conservative, recommended approach)
• Common dose: 10–20 mg/day
• Upper range: 20–40 mg/day (some practitioners suggest, but higher risk)

Forms available:

• Oral capsules — the most common consumer form. Dihexa was specifically designed for oral bioavailability, which is unusual for a peptide.
• Sublingual — some users dissolve under the tongue for faster absorption
• Nasal spray — may provide more direct CNS access, available from some suppliers

Pro Tip: If you’re going to try Dihexa, start at 5 mg daily for at least two weeks before considering an increase. This isn’t a compound where more is necessarily better, and there’s no established dose-response curve in humans to guide you. Take it in the morning on an empty stomach — several users report it can interfere with sleep if taken later in the day.

Cycling: No established protocol exists. The community generally suggests 4–8 weeks on, 2–4 weeks off. Given the unknowns around long-term HGF/c-Met activation, cycling seems prudent.

The Side Effects Nobody Warns You About

Commonly reported:

• Vivid dreams — this is nearly universal among users. Some describe them as cinematic, others as uncomfortably intense
• Headaches — especially during the first week, typically mild
• Anxiety or restlessness — a “wired” feeling, particularly at higher doses
• Irritability — mood shifts that some users find significant
• Mild GI discomfort — occasional reports

The serious concern — cancer risk:

This is the elephant in the room that most nootropics blogs gloss over. The HGF/c-Met signaling pathway is a well-established oncogenic pathway. Aberrant c-Met activation is directly implicated in the growth and metastasis of numerous cancers. By design, Dihexa potentiates this exact system.

Important: No studies have tested the long-term safety of Dihexa treatment, including its potential effects on tumor growth and cancer progression. The Alzheimer’s Drug Discovery Foundation explicitly flags this concern. If you have any history of cancer, active malignancy, or significant family cancer risk, this compound warrants extreme caution or outright avoidance.

Other contraindications:

• Pregnancy or nursing — completely unstudied
• Anyone under 18 — no safety data in developing brains
• Liver disease — HGF/c-Met is heavily involved in liver biology
• Concurrent cancer treatment — potential pathway conflicts

No formal drug interaction studies exist for Dihexa. That’s not reassuring — it means we’re flying blind.

Stacking Dihexa

Given that Dihexa operates through a growth factor pathway rather than neurotransmitter modulation, it theoretically pairs with nootropics that work through different mechanisms. But I want to emphasize: no combination has been studied for safety.

Commonly reported combinations:

• Semax or Selank — these work through BDNF/NGF pathways, which are mechanistically distinct from HGF/c-Met. Some users report complementary cognitive effects.
• Noopept — another BDNF/NGF modulator with a much longer safety track record. A reasonable pairing if you want neurotrophic support through multiple channels.
• Alpha-GPC or Citicoline — cholinergic support that complements any cognitive protocol.

What to be careful with:

• Stacking multiple growth-factor-promoting compounds (Dihexa + Cerebrolysin + 7,8-DHF, for instance) could compound the theoretical cancer risk. You’re stimulating cell growth through multiple pathways simultaneously with zero safety data on the combination.
• Combining with other experimental peptides multiplies unknown risks exponentially. Each compound alone has gaps in safety data — together, you’re in truly uncharted territory.

My Take

I’ve gone back and forth on Dihexa more than almost any compound I’ve covered. The mechanism is genuinely interesting — real synaptogenesis, not just neurotransmitter tweaking — and the independent stem cell research confirms the compound does interact with HGF in meaningful ways. The Chinese Alzheimer’s mouse study is legitimately encouraging.

But I can’t ignore the full picture. Retracted papers. Fabricated data. A failed Phase 2/3 trial of the related pharmaceutical compound. Theoretical cancer risk from the very pathway it’s designed to activate. And zero human studies on Dihexa itself.

If you’re a healthy person looking for a cognitive edge, this is not where I’d start. Not even close. Compounds like Bacopa Monnieri, Lion’s Mane, and Citicoline offer cognitive support with actual human safety data and a fraction of the risk. Get your foundations right — gut health, sleep, stress management, exercise — before you even think about research peptides.

If you’re dealing with significant cognitive decline and have exhausted conventional options, I understand why Dihexa is tempting. The desperation for something that works is real. But please do this under medical supervision, with honest eyes about what the evidence actually shows and what it doesn’t.

The nootropics space is full of compounds where the marketing outran the science. Dihexa might be the most dramatic example. The mechanism is real enough to be worth watching. But right now, the gap between what’s claimed and what’s proven is wider than I’m comfortable with.

If you want neurotrophic support with better evidence, look at Semax, Cerebrolysin, or even NSI-189. They’re not as flashy, but the ground beneath them is a lot more solid.